BG62511B1 - Приложение на епинастин за лечение на болки - Google Patents

Приложение на епинастин за лечение на болки Download PDF

Info

Publication number
BG62511B1
BG62511B1 BG102408A BG10240898A BG62511B1 BG 62511 B1 BG62511 B1 BG 62511B1 BG 102408 A BG102408 A BG 102408A BG 10240898 A BG10240898 A BG 10240898A BG 62511 B1 BG62511 B1 BG 62511B1
Authority
BG
Bulgaria
Prior art keywords
epinastine
pain
treatment
enantiomers
racemate
Prior art date
Application number
BG102408A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102408A (en
Inventor
Birgit Jung
Christopher J. Meade
Michel Pairet
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of BG102408A publication Critical patent/BG102408A/xx
Publication of BG62511B1 publication Critical patent/BG62511B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
BG102408A 1995-11-14 1998-04-27 Приложение на епинастин за лечение на болки BG62511B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19542281A DE19542281C2 (de) 1995-11-14 1995-11-14 Verwendung von Epinastin für die Behandlung der Migräne
PCT/EP1996/004957 WO1997017971A1 (de) 1995-11-14 1996-11-13 Verwendung von epinastin für die behandlung von schmerzen

Publications (2)

Publication Number Publication Date
BG102408A BG102408A (en) 1998-12-30
BG62511B1 true BG62511B1 (bg) 2000-01-31

Family

ID=7777343

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102408A BG62511B1 (bg) 1995-11-14 1998-04-27 Приложение на епинастин за лечение на болки

Country Status (32)

Country Link
US (1) US5942503A (es)
EP (1) EP0861081B1 (es)
JP (2) JP4264850B2 (es)
KR (1) KR100435611B1 (es)
CN (1) CN1104242C (es)
AR (1) AR004321A1 (es)
AT (1) ATE213160T1 (es)
AU (1) AU706112B2 (es)
BG (1) BG62511B1 (es)
BR (1) BR9611502A (es)
CA (1) CA2232008C (es)
CO (1) CO4770978A1 (es)
CZ (1) CZ290115B6 (es)
DE (2) DE19542281C2 (es)
DK (1) DK0861081T3 (es)
EE (1) EE03512B1 (es)
ES (1) ES2171746T3 (es)
HK (1) HK1015280A1 (es)
HU (1) HU225759B1 (es)
IL (1) IL123601A (es)
NO (1) NO982172D0 (es)
NZ (1) NZ322467A (es)
PL (1) PL186615B1 (es)
PT (1) PT861081E (es)
RO (1) RO118373B1 (es)
RU (2) RU2238733C2 (es)
SK (1) SK61398A3 (es)
TR (1) TR199800853T2 (es)
TW (1) TW575423B (es)
UY (1) UY24354A1 (es)
WO (1) WO1997017971A1 (es)
ZA (1) ZA969520B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
AU3596500A (en) * 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
DE10152973A1 (de) * 2001-10-26 2003-05-08 Boehringer Ingelheim Int Neue trockene und wässrige Epinastin-Sirup-Formulierung
BR0313175A (pt) * 2002-08-02 2005-06-14 Boehringer Ingelheim Int Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina
CA2509023C (en) 2002-12-26 2011-05-24 Pozen Inc. Multilayer dosage forms containing nsaids and triptans
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
EP1901724A1 (en) * 2005-07-08 2008-03-26 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising epinastine
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007110380A1 (en) * 2006-03-25 2007-10-04 Boehringer Ingelheim International Gmbh Insect bite relief preparation comprising epinastine
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
EP1875899A1 (en) * 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
RU2464984C2 (ru) * 2007-11-22 2012-10-27 Общество с ограниченной ответственностью "МС-Вита" Нестероидное противовоспалительное лекарственное средство
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP3041506B1 (en) 2013-09-02 2022-12-14 The University of Melbourne A method of treatment
CN105708840A (zh) * 2014-12-01 2016-06-29 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀组合物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102041389B1 (ko) 2017-12-12 2019-11-27 (주)프론트바이오 N-(9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일)-2-하이드록시벤즈아미드 및 2-((9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일) 카바모일)페닐 아세테이트의 화합물, 이의 제조방법 및 이를 포함하는 항염증 및 진통제 조성물
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP7118579B1 (ja) 2020-04-16 2022-08-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP6963651B2 (ja) * 2020-04-16 2021-11-10 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung

Also Published As

Publication number Publication date
AU7623096A (en) 1997-06-05
DE19542281A1 (de) 1997-05-15
CZ290115B6 (cs) 2002-06-12
JP4264850B2 (ja) 2009-05-20
BG102408A (en) 1998-12-30
WO1997017971A1 (de) 1997-05-22
AR004321A1 (es) 1998-11-04
IL123601A (en) 2002-12-01
DE19542281C2 (de) 1997-12-04
DE59608738D1 (de) 2002-03-21
JP4850880B2 (ja) 2012-01-11
JP2009019050A (ja) 2009-01-29
MX9803206A (es) 1998-09-30
DK0861081T3 (da) 2002-05-27
EP0861081B1 (de) 2002-02-13
CA2232008C (en) 2004-01-06
UY24354A1 (es) 2001-10-25
EE9800158A (et) 1998-12-15
HUP9903489A3 (en) 2001-12-28
CA2232008A1 (en) 1997-05-22
KR100435611B1 (ko) 2005-01-13
TR199800853T2 (xx) 1998-09-21
IL123601A0 (en) 1998-10-30
PL186615B1 (pl) 2004-02-27
BR9611502A (pt) 1999-03-02
PL326653A1 (en) 1998-10-12
EP0861081A1 (de) 1998-09-02
KR19990067527A (ko) 1999-08-25
RU2217144C2 (ru) 2003-11-27
JP2000500446A (ja) 2000-01-18
HU225759B1 (en) 2007-08-28
TW575423B (en) 2004-02-11
CZ149898A3 (cs) 1998-10-14
RU2238733C2 (ru) 2004-10-27
AU706112B2 (en) 1999-06-10
US5942503A (en) 1999-08-24
HUP9903489A2 (hu) 2000-03-28
EE03512B1 (et) 2001-10-15
NO982172L (no) 1998-05-13
CO4770978A1 (es) 1999-04-30
ZA969520B (en) 1997-05-14
PT861081E (pt) 2002-06-28
HK1015280A1 (en) 1999-10-15
CN1104242C (zh) 2003-04-02
SK61398A3 (en) 1998-09-09
NO982172D0 (no) 1998-05-13
NZ322467A (en) 2000-01-28
RO118373B1 (ro) 2003-05-30
ES2171746T3 (es) 2002-09-16
CN1202111A (zh) 1998-12-16
ATE213160T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
BG62511B1 (bg) Приложение на епинастин за лечение на болки
JP3020808B2 (ja) 精神病治療薬としての４−フェニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミン誘導体の使用
US5166207A (en) Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
PT87958B (pt) Processo para a preparacao de composicoes farmaceuticas, contendo antagonistas 5ht-3
SK279237B6 (sk) Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl
EP0591434A1 (en) Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US6310085B1 (en) Method for the treatment of neurological or neuropsychiatric disorders
AU782492B2 (en) Method for the treatment of neurological or neuropsychiatric disorders
US20050054652A1 (en) Methods of treating metabolic syndrome using dopamine receptor agonists
RU2126254C1 (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, и способ лечения
CA2036375A1 (en) Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
US6855729B2 (en) Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US3726979A (en) Method of producing serotonin antagonism
Salonen et al. Clinical interactions with alpha-2-adrenergic agonists in anesthetic practice
US5519044A (en) Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
MXPA98003206A (es) Empleo de epinastina para el tratamiento de dolores
US20100099702A1 (en) Therapeutic agent for neuropathic pain
US3743746A (en) Process of treating peptic ulcer with a non-anticholinergic agent
JPH04173777A (ja) メラトニン類似体
Gardey-Levassort et al. Action of Probenecid on the Central Nervous System of the Rabbit: I. Effects on the Elimination of 5-Hydroxyindoleacetic Acid
US3808337A (en) Hoxy-benzamido-butyric acid
IL145696A (en) Use of melatonin antagonists in the preparation of pharmaceutical compositions for the treatment of neurological or neuropsychiatric disorders